Built by senior pharma consultants with 20+ years of pharma consulting experience, AXLRx™ compresses weeks of foundational engagement work into hours — delivering verified, decision-ready intelligence briefs as per report, with no subscription and no sales process.
MoatRx, a pharmaceutical consulting and operations firm specialising in commercial operations across the GCC and global markets, today announced the commercial launch of AXLRx™ — an AI-augmented pharma intelligence platform purpose-built for consulting engagements. Developed over six months of intensive build and validation cycles, AXLRx™ delivers consulting-grade intelligence briefs — disease landscapes, competitive intelligence, patient sizing models, market access analyses, and more — verified against live clinical and commercial data sources, in a single session.
Closing the Pharma Consulting Execution Gap
For more than two decades, Naresh Gupta — Founder and Director of MoatRx — has led commercial operations at organisations including ZS Associates, Novartis, and FutureBridge. Across global product launches, commercial analytics transformations, and capability-building programmes, one pattern repeated itself: even the best strategies stalled at execution.
“The gap between strategic intent and real-world delivery is where pharma companies lose the most value,” says Gupta. “MoatRx was founded on a single belief: execution is the true competitive advantage. AXLRx™ is how we make that execution faster, without making it less rigorous.”
Before AXLRx™, every consulting engagement began with the same three to four weeks of foundational work — indication landscape assessments, patient funnel development, competitive intelligence mapping, commercial opportunity sizing, and stakeholder alignment preparation. These activities were necessary but delayed critical decision-making. Traditional market research reports routinely exceeded 200 pages and were rarely tailored to a company’s specific business question. Generic AI tools offered speed but produced outputs requiring substantial rework, carried hallucination risk, and lacked pharmaceutical commercial context. Neither approach delivered working consulting assets.
AXLRx™: Acceleration, Not Replacement
AXLRx™ is not a research subscription. It is not a report generator. It is an execution accelerator for active pharma projects — built on the proprietary AI engine and shaped entirely around consultant workflows. The platform accepts a structured brief and returns a consulting-grade, peer-reviewed, decision-ready deliverable — complete with assumption registers, executive summaries written as decision memos, binding-constraint analyses, and live-verified citations traceable to their primary sources.
Every output passes through an automated AuditX quality gate. Briefs are structured using pyramid principle narrative architecture, MECE section logic, and a five-phase editorial process. Claims are sourced against live connectors — PubMed / MEDLINE, ClinicalTrials.gov, FDA, EMA, ICD-10, and the NPI Registry — and tagged by confidence tier (High / Medium / Low). No fabricated statistics. No unverified numbers.
Intelligence Briefs Available at Launch
Disease Landscape (PDF) — Full indication profile covering epidemiology, treatment architecture, clinical evidence landscape, and commercial context. Any indication × geography.
Competitive Intelligence Brief (PDF) — Head-to-head competitive analysis with through-line narrative, market share dynamics, pipeline threats, and strategic decision anchors.
Market Access & Formulary Strategy (PDF) — Payer landscape, reimbursement pathway, pricing corridor, HTA context, and access barriers — with GCC regulatory frameworks (SFDA, MOHAP, DHA, MOPH) natively integrated.
Pipeline Tracker (PDF) — Clinical trial landscape, development timelines, endpoint benchmarking, and competitive threat assessment for a given indication.
Competitor War Game Brief (PDF) — Red-team pre-launch strategy from the competitor’s perspective — capability architecture, backcast roadmap, and strategic questions for the buyer team.
Patient Sizing Model (Excel) — Top-down epidemiology funnel from prevalence to eligible patient pool — single or multi-country with sensitivity analysis and assumption register.
Revenue Forecast Model (Excel) — Base / Bull / Bear revenue projections with analogue anchoring, scenario modelling, and assumption documentation.
HCP Discussion Guide (Word) — 60-minute qualitative KOL interview guide, modular by indication, research objective, and respondent type.
Purpose-Built for Difficult to source Indications and Emerging Markets
AXLRx™ was designed to ensure client gets verified information for emerging market and regions such as GCC, LATAM or others where pharmaceutical commercial operations are maturing rapidly, specialty and rare disease portfolios are expanding, and reliable, locally-grounded market intelligence has historically been either prohibitively expensive or simply unavailable.
The platform also serves pharma vendors, CROs, agency partners, Global Capability Centres (GCCs), and consulting teams that support client projects and need research-grade working documents at speed. Customised solutions across specific indications, geographies, or brief types can be configured within days.
Pricing and Availability
Delivery: Typically same business day
Verification standard: Client-ready — live T1/T2 connector data, AuditX gate
Engagement: Direct via MoatRx now. Self-serve web platform: Q3/Q4 2026 (planned)
LAUNCH OFFER — COMPLIMENTARY FIRST BRIEF
To demonstrate the platform’s capabilities, MoatRx is offering a complimentary first intelligence brief for organisations preparing for a strategy engagement, commercial launch, competitive assessment, or business development initiative. Connect with Naresh Gupta and the MoatRx team to experience how AXLRx™ transforms commercial consulting preparation into decision-ready business intelligence.
“While ideas start the journey, execution determines success. With AXLRx™, execution — and the intelligence that makes it possible — can begin on the same day the brief is submitted.”
— Naresh Gupta, Founder & Director, MoatRx
